

Clinical Policy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Reference Number: ERX.NPA.138

Effective Date: 03.01.20

Last Review Date: 02.22

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

The following agents contain a dipeptidyl peptidase-4 (DPP-4) inhibitor and require prior authorization*: alogliptin (Nesina®), alogliptin/metformin (Kazano®), alogliptin/pioglitazone (Oseni®), linagliptin (Tradjenta®), linagliptin/metformin (Jentadueto®, Jentadueto® XR), saxagliptin (Onglyza®), saxagliptin/metformin (Kombiglyze® XR), sitagliptin (Januvia®), and sitagliptin/metformin (Janumet®, Janumet® XR).

**If request is for a combination DPP-4 inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor (e.g., linagliptin/empagliflozin [Glyxambi®], linagliptin/empagliflozin/metformin [Trijardy™ XR], saxagliptin/dapagliflozin [Qtern®], sitagliptin/ertugliflozin [Steglujan™]), refer to ERX.NPA.136 SGLT2 Inhibitors.*

FDA Approved Indication(s)

DPP-4 inhibitors are indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitation(s) of use:

- DPP-4 inhibitors should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- DPP-4 inhibitors have not been studied in patients with a history of pancreatitis.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that DPP-4 inhibitors are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Type 2 Diabetes Mellitus (must meet all):

1. Diagnosis of type 2 diabetes mellitus;
2. Age ≥ 18 years;
3. Member meets one of the following (a or b):
 - a. Failure of ≥ 3 consecutive months of metformin, unless contraindicated or clinically significant adverse effects are experienced;
 - b. For antidiabetic medication-naïve members, requested agent is approvable if intended for concurrent use with metformin due to HbA1c ≥ 8.5% (drawn within the past 3 months);
4. If request is for a non-preferred DPP-4 inhibitor, failure of ≥ 3 consecutive months of a preferred DPP-4 inhibitor, unless clinically significant adverse effects are experienced or all are contraindicated;
5. Dose does not exceed the FDA approved maximum recommended dose (see Section V).

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Type 2 Diabetes Mellitus (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed the FDA approved maximum recommended dose (see Section V).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AACE: American Association of Clinical Endocrinologists
 ACE: American College of Endocrinology
 ADA: American Diabetes Association
 DPP-4: dipeptidyl peptidase-4

FDA: Food and Drug Administration
 GLP-1: glucagon-like peptide-1
 HbA1c: glycated hemoglobin
 SGLT2: sodium-glucose co-transporter 2

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
metformin (Fortamet®, Glucophage®, Glucophage® XR, Glumetza®)	Regular-release (Glucophage): 500 mg PO BID or 850 mg PO QD; increase as needed in increments of 500 mg/week or 850 mg every 2 weeks Extended-release: <ul style="list-style-type: none"> • Fortamet, Glumetza: 1,000 mg PO QD; increase as needed in increments of 500 mg/week • Glucophage XR: 500 mg PO QD; increase as needed in increments of 500 mg/week 	Regular-release: 2,550 mg/day Extended-release: 2,000 mg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - History of serious hypersensitivity reaction to the requested drug product
 - Severe renal impairment (*metformin-containing products*)
 - Acute or chronic metabolic acidosis, including diabetic ketoacidosis (*metformin-containing products only*)
 - NYHA Class III or IV heart failure (*Oseni only*)
- Boxed warning(s): lactic acidosis (*metformin-containing products only*), congestive heart failure (*Oseni only*)

Appendix D: General Information

- Per the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists and American College of Endocrinology (AAACE/ACE) guidelines:
 - Metformin is recommended for all patients with type 2 diabetes. Monotherapy is recommended for most patients; however:
 - Starting with dual therapy (i.e., metformin plus another agent, such as a sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT2 inhibitor, glucagon-like peptide 1 [GLP-1] receptor agonist, or basal insulin) may be considered for patients with baseline HbA1c \geq 1.5% above their target per the ADA (\geq 7.5% per the AAACE/ACE). According to the ADA, a reasonable HbA1c target for many non-pregnant adults is $<$ 7% (\leq 6.5% per the AAACE/ACE).
 - Starting with combination therapy with insulin may be considered for patients with baseline HbA1c $>$ 10% per the ADA ($>$ 9% if symptoms are present per the AAACE/ACE).
 - If the target HbA1c is not achieved after approximately 3 months of monotherapy, dual therapy should be initiated. If dual therapy is inadequate after 3 months, triple therapy should be initiated. Finally, if triple therapy fails to bring a patient to goal, combination therapy with insulin should be initiated. Each non-insulin agent added to initial therapy can lower HbA1c by 0.7-1%.

V. Dosage and Administration

Drug Name	Dosing Regimen	Maximum Dose
Janumet (sitagliptin/metformin)	Individualized dose PO BID	100/2,000 mg/day
Janumet XR (sitagliptin/metformin)	Individualized dose PO QD	100/2,000 mg/day
Januvia (sitagliptin)	100 mg PO QD	100 mg/day
Jentadueto (linagliptin/metformin)	Individualized dose PO BID	5/2,000 mg/day
Jentadueto XR (linagliptin/metformin)	Individualized dose PO QD	5/2,000 mg/day
Kazano (alogliptin/metformin)	Individualized dose PO BID	25/2,000 mg/day
Kombiglyze XR (saxagliptin/metformin)	Individualized dose PO QD	5/2,000 mg/day
Nesina (alogliptin)	25 mg PO QD	25 mg/day
Onglyza (saxagliptin)	2.5 or 5 mg PO QD	5 mg/day
Oseni (alogliptin/pioglitazone)	Individualized dose PO QD	25/45 mg/day
Tradjenta (linagliptin)	5 mg PO QD	5 mg/day

VI. Product Availability

Drug Name	Availability
Janumet (sitagliptin/metformin)	Tablets: 50/500 mg, 50/1,000 mg
Janumet XR (sitagliptin/metformin)	Tablets: 100/1,000 mg, 50/500 mg, 50/1,000 mg
Januvia (sitagliptin)	Tablets: 25 mg, 50 mg, 100 mg
Jentadueto (linagliptin/metformin)	Tablets: 2.5/500 mg, 2.5/850 mg, 2.5/1,000 mg
Jentadueto XR (linagliptin/metformin)	Tablets: 5/1,000 mg, 2.5/1,000 mg
Kazano (alogliptin/metformin)	Tablets: 12.5/500 mg, 12.5/1,000 mg
Kombiglyze XR (saxagliptin/metformin)	Tablets: 5/500 mg, 5/1,000 mg, 2.5/1,000 mg
Nesina (alogliptin)	Tablets: 6.25 mg, 12.5 mg, 25 mg
Onglyza (saxagliptin)	Tablets: 2.5 mg, 5 mg

Drug Name	Availability
Oseni (alogliptin/pioglitazone)	Tablets: 12.5/15 mg, 12.5/30 mg, 12.5/45 mg, 25/15 mg, 25/30 mg, 25/45 mg
Tradjenta (linagliptin)	Tablets: 5 mg

VII. References

- American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care. 2021; 44(suppl 1): S1-S232. Updated June 16, 2021. Accessed September 16, 2021.
- Janumet Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021. Available at: www.janumet.com. Accessed September 16, 2021.
- Janumet XR Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021. Available at: www.janumetxr.com. Accessed September 16, 2021.
- Januvia Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; December 2020. Available at: www.januvia.com. Accessed September 16, 2021.
- Jentadueto Prescribing Information Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.jentadueto.com. Accessed September 16, 2021.
- Jentadueto XR Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.jentaduetoxr.com. Accessed September 16, 2021.
- Kazano Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2019. Available at: www.nesinafamily.com. Accessed September 16, 2021.
- Kombiglyze XR Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2019. Available at: www.kombiglyzexr.com. Accessed September 16, 2021.
- Nesina Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2019. Available at: www.nesinafamily.com. Accessed September 16, 2021.
- Onglyza Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2019. Available at: www.onglyza.com. Accessed September 16, 2021.
- Oseni Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2019. Available at: www.nesinafamily.com. Accessed September 16, 2021.
- Tradjenta Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020. Available at: www.tradjenta.com. Accessed September 16, 2021.
- Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020; 26(1): 107-139.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created: adapted from ERX.ST.33 DPP-4 inhibitors; added diagnosis, age, and positive response requirements; added Trijardy XR; references reviewed and updated.	10.29.19	02.20
Allowed bypass of preferred agents for patients with established cardiovascular disease/risk factors or diabetic nephropathy requesting a dapagliflozin- or empagliflozin-containing product per previously approved clinical guidance.	04.14.20	
1Q 2021 annual review: removed criteria for combination DPP4/SGLT2 products and directed requests to the SGLT2 policy instead; references reviewed and updated.	10.27.20	02.21
1Q 2022 annual review: no significant changes; references reviewed and updated.	09.16.21	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of

physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2020 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.